BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioLife Solutions reports record revenue and projects strong growth

BioLife Solutions delivered strong financial performance in Q4 2022, with record revenue and growth across key revenue platforms.
Despite challenges in operating expenses and gross margin, the company remains optimistic about future growth and profitability.
By focusing on high-margin revenues, supply chain enhancements, and allogeneic therapies, BioLife is strategically positioned for long-term success.

BioLife Solutions reports revenue growth and strategic business evaluation

BioLife Solutions reported solid Q1 2023 performance with revenue growth and improved gross margin, despite short-term EBITDA challenges.
The company is strategically evaluating underperforming businesses while focusing on high-margin recurring revenue streams for future growth.
CEO's balanced approach of maintaining strengths and exploring new projects signals a commitment to sustainable profitability and innovation.
BioLife's emphasis on efficiency and strategic planning positions it well for navigating market uncertainties and driving long-term success.

BioLife Solutions reports Q2 revenue decline, focuses on strategic growth

BioLife Solutions navigated challenges in Q2 2023 with a strategic focus on higher-margin streams and a strong pipeline for growth.
Despite a decrease in revenue and challenges in key markets, the company's divestiture plans and revenue guidance reflect confidence in future performance.
Analysts' concerns about capacity constraints and operational challenges highlight areas for improvement and strategic focus for BioLife Solutions.

BioLife Solutions faces revenue decline in Q3 but eyes market growth

BioLife Solutions navigated challenges in Q3 2023 with a decline in revenue and negative adjusted EBITDA, but remains optimistic about its market position and potential for revenue recovery. Strategic divestiture plans and a focus on core products aim to drive profitability and growth.

BioLife Solutions reports 11% revenue decrease in 2023

BioLife Solutions navigated revenue challenges in 2023, with a focus on higher margin revenue streams and operational efficiency.
Despite revenue declines, the company remains optimistic about future growth opportunities in the cell processing sector.
Proactive supply chain management and a diversified supplier base position BioLife well to mitigate risks and ensure operational continuity.
Strategic plans to divest underperforming product lines and optimize operations indicate a path towards improved financial performance.

BioLife Solutions excels in Q3, shifts focus to high-margin CGT tools

BioLife Solutions demonstrated robust performance in Q3 2024, driven by strong revenue growth and strategic divestment decisions.
The company's focus on becoming a pure-play CGT tools provider and emphasis on high-margin products signal a clear strategic direction.
While facing challenges in transitioning its business model, BioLife is well-equipped to capitalize on opportunities in the growing biopreservation market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and positive adjusted EBITDA Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

BOTHELL, Wash. , Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024.

BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024

Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash. , Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

BioLife Solutions, Inc. is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. The company offers bioproduction tools and services for the cell and gene therapy industry, with recurring revenue streams making up about 65% of its revenue. The cell and gene therapy market is expected to continue growing, but BioLife's recent financial performance and management changes have caused concern.

BioLife Solutions: A Complicated Tale

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Rod de Greef - Chairman and CEO Conference Call Participants Jacob Johnson - Stephen Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Steven Mah - TD Cowen Thomas Flaten - Lake Street Michael Okunewitch - Maxim Group Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst Conference Call.

BioLife Solutions, Inc. (BLFS) Q3 2023 Earnings Call Transcript

Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports Third Quarter 2023 Financial Results

BOTHELL, Wash. , Nov. 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023.

BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of $33.3 million and expect 2023 revenue at the low end of the previously announced guidance range  BOTHELL, Wash. , Oct. 19, 2023 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced Roderick de Greef has been appointed as Chairman of the Board of Directors and Chief Executive Officer replacing Michael Rice who is retiring after a seventeen year tenure, effective immediately.

BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023

BioLife is facing setbacks due to a difficult funding environment, inventory corrections, and a decline in COVID-related revenues. The company's acquisitions have negatively impacted margins and cash flow. Management plans to divest the freezer business, which is expected to improve financials and the balance sheet and will provide an impetus for the stock.

BioLife Hit By An Inventory Correction

Allakos Inc

Cano Health

Kezar Life Sciences Inc

Alaunos Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter.

Why Shares of BioLife Solutions Plummeted This Week

BioLife Solutions said it is divesting itself of some assets to focus on its higher-margin business. The company saw declining revenue but narrowed its losses dramatically.

Why Shares of BioLife Solutions Are Slumping on Wednesday

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago.

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates

Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business

BOTHELL, Wash. , July 27, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter financial results will be released after market close on Tuesday, August 8, 2023.

BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023

BOTHELL, Wash. , June 14, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that all of its SciSafe-branded biostorage facilities in the USA have been accredited by the College of American Pathologists (CAP).

BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities

Large-Capacity Tabletop Freezer Expands Line of Controlled-Rate Freezers for Cell and Gene Therapies; Now Available for Order BOTHELL, Wash. , June 6, 2023 /PRNewswire/ -- BioLife Solutions, Inc.  (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced the launch of a new, large-capacity controlled-rate freezer (CRF) to expand its CRF product line, which now stands at three different form factors.

BioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Michael Rice - Chairman & CEO Conference Call Participants Jacob Johnson - Stephens Inc. Thomas Flaten - Lake Street Capital Markets Chad Wiatrowski - TD Cowen Carl Byrnes - Northland Capital Markets Yuan Zhi - B. Riley Securities Paul Knight - KeyBanc Capital Markets Operator Hello.

BioLife Solutions, Inc. (BLFS) Q1 2023 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates

Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022 Decision to Explore Strategic Alternatives for Ultra-Low Temperature and Cryogenic Freezer Product Lines Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports First Quarter 2023 Financial Results

BOTHELL, Wash., May 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter financial results will be released after market close on Wednesday, May 10, 2023.

BioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023

BioLife Solutions, a leading provider of bioproduction tools and services, is poised for growth as the demand for biologics and regenerative medicine increases. CryoStor and HypoThermosol have shown significant improvement to the post-preservation viability of biologic materials during manufacturing, storage, and distribution.

BioLife Solutions: Capitalizing On The Future Of Biopreservation

An acquisition spree has produced a host of problems, costs, write-offs, a collapse in gross margins and profits, cash bleed, and significant dilution. While only the evo and Sexton acquisitions have been a real success, the problems at some of the others now seem to be largely in the rearview mirror.

BioLife Solutions Is Set To Finally Absorb Its Acquisitions

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Yuan Zhi – B. Riley Thomas Flaten – Lake Street Operator Good day, and welcome to the BioLife Solutions' Fourth Quarter 2022 and Full Year Earnings Call.

BioLife Solutions, Inc. (BLFS) Q4 2022 Earnings Call Transcript

Record full year revenue of $161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and services supplier Record Q4 2022 revenue of $44.3 million increased 19% over 2021; biopreservation media revenue growth of 35% Full year adjusted EBITDA of $3.6 million and Q4 2022 adjusted EBITDA of $1.7 million Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

News for BioLife Solutions Stock (BLFS)